WASHINGTON, DC (February 15, 2023) — The Association for Accessible Medicines (AAM) today issued a statement on the latest CMMI report:
“As the Biden Administration has recognized in its Comprehensive Plan for Addressing High Drug Prices, lower-cost generic and biosimilar medicines hold enormous promise to reduce prescription drug costs and increase access for seniors,” said Craig Burton, Executive Director of the Biosimilars Council and Senior Vice President of Policy & Strategic Alliances at AAM. “Perverse incentives, however, are leading to delayed coverage and preventing patient access to these lower-cost medicines. CMMI can and should do more to test new models that accelerate seniors’ access to generic and biosimilar medicines and reduce patients’ costs on already low-priced generics. The steps CMMI intends to take, while positive, should be turbocharged to enhance the benefit for America’s seniors.”
MEDIA CONTACT:
Susan Reilly
Director of Communications, AAM
1.703.725.0729
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
